En español
NIDA

NIDA Notes Articles: Clinical Trials Network

NIDA Notes Category Graphic

Women and Sex/Gender Differences Research Program

April 2012
NIDA’s Women and Sex/Gender Differences Research Program focuses on gender-specific addiction risk factors and treatment needs.

NIDA Notes Category Graphic

Study Endorses Onsite HIV Testing Without Risk Reduction Counseling

April 2013
Patients were more likely to take a rapid HIV test when substance abuse treatment programs offered the test onsite rather than referred for offsite testing. Patients were equally likely to accept and learn their HIV status whether the offer of onsite testing was accompanied by 30 minutes of risk reduction counseling or by 5 minutes of brief information on the testing procedure. Onsite testing accompanied by brief information was cost effective, taking into account the projected lifetime costs of treatment and the gains in health and longevity for detected cases.

NIDA Notes Category Graphic

Medications That Treat Opioid Addiction Do Not Impair Liver Health

December 2013
A trial of buprenorphine/naloxone (Bup/Nx) showed no evidence that the medicine was associated with liver damage. The drug gave results similar to those of methadone. The study data indicate that although most patients can be treated safely with either methadone or Bup/Nx without major concern for liver injury, clinicians are advised to continue to monitor the liver health of their patients who are on methadone or Bup/Nx therapy.

NIDA Notes Category Graphic

Dr. Kevin M. Gray Q & A: A Potential Medication for Marijuana Dependence

October 2014
Dr. Kevin M. Gray discusses why it’s the perfect time for discovering new evidence-based treatments for marijuana dependence. In an accompanying podcast, he discusses a clinical trial that examines NAC’s potential as a treatment for marijuana dependence among adults.

NIDA Notes Category Graphic

After Showing Promise for Cannabis-Using Adolescents, N-Acetylcysteine Falters in Adult Study

September 2017
In a clinical trial, N-acetylcysteine did not help adults reduce their cannabis use, despite having been effective for adolescents in a previous trial. The results indicated that if adults are able to benefit from the medication, they will likely require a different treatment regimen than adolescents.

Pages

NIDA Notes

Tags

Drug Topics

Drugs of Abuse

Population Groups

Related Topics